CMA
AXSM icon

Cedar Mountain Advisors’s Axsome Therapeutics AXSM Stock Holding History

Cedar Mountain Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2K Hold
66
– – ﹤0.01% 391
2026
Q1 		$11.2K Buy
+66
New +$11.4K ﹤0.01% 431

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return

Cedar Mountain Advisors's AXSM Position: Q2 2026 in Review

Cedar Mountain Advisors held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 66 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #391.

Cedar Mountain Advisors first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Cedar Mountain Advisors held 66 shares of Axsome Therapeutics worth $16.2K as of Q2 2026.
  • Cedar Mountain Advisors left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #391 holding.
  • Cedar Mountain Advisors first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.